Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TriSalus Life SciencesTLSI -0.53%48 Operating Cash Flow per Share is $-0.44 as of Jun. 2026. GuruFocus rates TLSI with a GF Score™ of 48/100 and a GF Value™ of $3.76 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 652 Medical Devices & Instruments companies, TriSalus Life Sciences ranks better than 95.55% on this metric.
TriSalus Life Sciences's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.17.
TriSalus Life Sciences's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.44.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 83.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for TriSalus Life Sciences's Operating Cash Flow per Share or its related term are showing as below:
TLSI'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 72 Med: 77.7 Max: 83.4
Current: 83.4
During the past 5 years, TriSalus Life Sciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 83.40% per year. The lowest was 72.00% per year. And the median was 77.70% per year.
TLSI's 3-Year OCF Growth Rate is ranked better than 95.55% of 652
companies
in the Medical Devices & Instruments industry
Industry Median: 12.7
vs TLSI: 83.40
TriSalus Life Sciences Operating Cash Flow per Share Related Terms
TriSalus Life Sciences Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences Operating Cash Flow per Share Chart
TLSI vs CV, RXST, TMCI: Operating Cash Flow per Share Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Price-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.44 mean?
TriSalus Life Sciences (TLSI) has a Operating Cash Flow per Share of $-0.44 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #29 out of 652 companies in the Medical Devices & Instruments industry, placing it in the top 4.4%.
Is TriSalus Life Sciences' Operating Cash Flow per Share too high?
TriSalus Life Sciences' current Operating Cash Flow per Share is $-0.44. Based on the distribution chart, TriSalus Life Sciences ranks #29 out of 652 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 48/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Operating Cash Flow per Share compare to CV and RXST?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #29 out of 652 companies for Operating Cash Flow per Share. This places TriSalus Life Sciences in the top 4% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 12.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Medical Devices & Instruments company?
The median Operating Cash Flow per Share among Medical Devices & Instruments companies is 12.70, based on 652 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Operating Cash Flow per Share is 12.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Operating Cash Flow per Share is $-0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.76, compared to a current price of $4.67 — trading 24.1% above its estimated fair value. The current Operating Cash Flow per Share is $-0.44. TriSalus Life Sciences' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Operating Cash Flow per Share is $-0.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be overvalued.
The current stock price of $4.67 is trading 24.1% above its estimated GF Value™ of $3.76.
GuruFocus considers TriSalus Life Sciences to be Modestly Overvalued.
Key valuation signals for TLSI:
Operating Cash Flow per Share: $-0.44
GF Value™: $3.76 vs. price of $4.67 (24.1% above fair value)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
48GF Score
Get the complete analysis for TLSI
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
